Tags

Type your tag names separated by a space and hit enter

European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Curr Med Res Opin. 2006 Dec; 22(12):2375-81.CM

Abstract

OBJECTIVE

To determine participant preference for weekly versus monthly bisphosphonate therapy for osteoporosis after being informed about differences in fracture efficacy.

DESIGN

20-minute, semi-structured, face-to-face or telephone interviews. Two bisphosphonate choices were presented on the basis of block randomization: weekly therapy with proven efficacy to reduce fracture risk at the spine and hip, or monthly therapy with proven efficacy to reduce fracture risk at the spine but not the hip.

SUBJECTS

Women from the UK, Germany, France, Spain and Italy, with postmenopausal osteoporosis and aged > or = 55 years. Fifty percent were currently taking a weekly bisphosphonate; 50% had no history of taking any bisphosphonate.

MEASURES

An efficacy rating scale and an intention-to-use rating scale were developed for this study. The primary endpoint was preference for weekly or monthly therapy. Reasons for preference were recorded.

RESULTS

A preference was recorded for 1248 women (1253 were recruited). More women preferred weekly to monthly therapy (82% vs. 18%, respectively; p < 0.001). Among women who preferred weekly therapy, efficacy was the most commonly cited reason (65%). Ninety-two percent of the total cohort rated the efficacy of the weekly therapy as 'excellent/good' versus 38% for monthly (p < 0.001). Sixty-nine percent intended to use weekly bisphosphonates compared with 34% for monthly (p < 0.001).

CONCLUSIONS

When informed about differences in fracture efficacy in weekly and monthly bisphosphonates, a significantly greater proportion (82%) of women preferred a weekly bisphosphonate with proven fracture efficacy at the spine and hip over a monthly bisphosphonate with proven fracture efficacy only at the spine.

Links

Publisher Full Text

Authors+Show Affiliations

Keen R
The Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, UK. richard.keen@ucl.ac.uk
Jodar E
No affiliation info available
Iolascon G
No affiliation info available
Kruse HP
No affiliation info available
Varbanov A
No affiliation info available
Mann B
No affiliation info available
Gold DT
No affiliation info available

MeSH

AgedAlendronateBone Density Conservation AgentsDrug Administration ScheduleEtidronic AcidEuropeFemaleHumansInterviews as TopicMiddle AgedOsteoporosis, PostmenopausalPatient CompliancePatient SatisfactionRisedronic Acid

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17257451

Citation

Keen, Richard, et al. "European Women's Preference for Osteoporosis Treatment: Influence of Clinical Effectiveness and Dosing Frequency." Current Medical Research and Opinion, vol. 22, no. 12, 2006, pp. 2375-81.
Keen R, Jodar E, Iolascon G, et al. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin. 2006;22(12):2375-81.
Keen, R., Jodar, E., Iolascon, G., Kruse, H. P., Varbanov, A., Mann, B., & Gold, D. T. (2006). European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Current Medical Research and Opinion, 22(12), 2375-81.
Keen R, et al. European Women's Preference for Osteoporosis Treatment: Influence of Clinical Effectiveness and Dosing Frequency. Curr Med Res Opin. 2006;22(12):2375-81. PubMed PMID: 17257451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. AU - Keen,Richard, AU - Jodar,Esteban, AU - Iolascon,Giovanni, AU - Kruse,Hans-Peter, AU - Varbanov,Alex, AU - Mann,Birgit, AU - Gold,Deborah T, PY - 2007/1/30/pubmed PY - 2007/3/14/medline PY - 2007/1/30/entrez SP - 2375 EP - 81 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 22 IS - 12 N2 - OBJECTIVE: To determine participant preference for weekly versus monthly bisphosphonate therapy for osteoporosis after being informed about differences in fracture efficacy. DESIGN: 20-minute, semi-structured, face-to-face or telephone interviews. Two bisphosphonate choices were presented on the basis of block randomization: weekly therapy with proven efficacy to reduce fracture risk at the spine and hip, or monthly therapy with proven efficacy to reduce fracture risk at the spine but not the hip. SUBJECTS: Women from the UK, Germany, France, Spain and Italy, with postmenopausal osteoporosis and aged > or = 55 years. Fifty percent were currently taking a weekly bisphosphonate; 50% had no history of taking any bisphosphonate. MEASURES: An efficacy rating scale and an intention-to-use rating scale were developed for this study. The primary endpoint was preference for weekly or monthly therapy. Reasons for preference were recorded. RESULTS: A preference was recorded for 1248 women (1253 were recruited). More women preferred weekly to monthly therapy (82% vs. 18%, respectively; p < 0.001). Among women who preferred weekly therapy, efficacy was the most commonly cited reason (65%). Ninety-two percent of the total cohort rated the efficacy of the weekly therapy as 'excellent/good' versus 38% for monthly (p < 0.001). Sixty-nine percent intended to use weekly bisphosphonates compared with 34% for monthly (p < 0.001). CONCLUSIONS: When informed about differences in fracture efficacy in weekly and monthly bisphosphonates, a significantly greater proportion (82%) of women preferred a weekly bisphosphonate with proven fracture efficacy at the spine and hip over a monthly bisphosphonate with proven fracture efficacy only at the spine. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/17257451/European_women's_preference_for_osteoporosis_treatment:_influence_of_clinical_effectiveness_and_dosing_frequency_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079906X154079 DB - PRIME DP - Unbound Medicine ER -